Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

Also called NCT02055976

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 218 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02055976
Other papers using this trial's data
  • Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study Circulation journal : official journal of the Japanese Circulation Society, 2017-09-25 DOI, PubMed 28539539

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02055976. Randomized; triple masking; primary purpose treatment. Start 2014-03 (actual); primary completion 2015-01 (actual). Results posted on 2019-02-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects
Condition
Hypercholesterolemia
Intervention (Drug)
Bococizumab (PF-04950615;RN316)
Intervention (Drug)
Bococizumab (PF-04950615;RN316)
Intervention (Drug)
Bococizumab (PF-04950615;RN316)
Intervention (Drug)
Placebo
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Bococizumab (PF-04950615;RN316)
Intervention (Drug)
Bococizumab (PF-04950615;RN316)
Intervention (Drug)
Bococizumab (PF-04950615;RN316)
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct02055976
Content hash
b2c38ca8d47f3b23e2307728f80d43964befc801925cc59320d378f4d7ee25ea